Search our Database of Scientific Publications and Authors

I’m looking for a

    1236 results match your criteria Aktuelle Urologie[Journal]

    1 OF 25

    [Immunotherapy for renal cell carcinoma - current status].
    Aktuelle Urol 2018 Apr 27;49(2):187-191. Epub 2018 Mar 27.
    Universitätsklinikum Jena, Urologische Klinik und Poliklinik, Jena.
    Systemic treatment of metastatic renal cell carcinoma (mRCC) has substantially changed during the last 2 years due to approval of the immune-checkpoint inhibitor Nivolumab (Opdivo) and new multikinase inhibitors (Cabozantinib, Lenvatinib, Tivozanib). The german kidney tumor guideline strongly recommends Nivolumab and Cabozantinib as 2nd line treatments after prior VEGF targeted therapy. CheckMate 025, the prospective randomized trial which led to approval of Nivolumab demonstrated improved overall survival (26 month vs. Read More

    [Immune checkpoint inhibition in metastatic urothelial carcinoma].
    Aktuelle Urol 2018 Apr 27;49(2):178-186. Epub 2018 Mar 27.
    Universitätsklinikum Tübingen, Klinik für Urologie, Tübingen.
    The treatment of metastatic urothelial carcinoma is characterized by the administration of combinatory regimes of chemotherapy. In the first-line treatment theses regimes demonstrate relatively good objective response rates and prolongation of overall survival. The prognosis declines if the patient is refractory to platin in the second- or third-line treatment or if the patient is ineligible for cisplatin in the first-line setting. Read More

    [The role of biomarkers in the diagnosis, prognosis and therapy of patients with immuno-oncological treatments of genito-urinary carcinomas].
    Aktuelle Urol 2018 Apr 27;49(2):171-177. Epub 2018 Mar 27.
    Service d'Anatomie et Cytologie Pathologiques, Hôpital Tenon.
    In recent years, fundamental research has yielded new insights into tumour biology, and new treatments have been developed. This review highlights the role of the pathologist and how he can support clinicians to find the right treatment for each patient. We explain the problems of the molecular subgroups of bladder cancer, the role of neo-adjuvant chemotherapy in the context of these findings, and show the important role of checkpoint inhibitors. Read More

    [Immunotherapy with checkpoint inhibitors in local advanced and metastatic urothelial carcinoma].
    Aktuelle Urol 2018 Apr 27;49(2):142-156. Epub 2018 Mar 27.
    Universitätsklinik für Urologie, Universitätsklinikum Tübingen.
    The approval of immune checkpoint inhibitors has started a new era in the treatment of urothelial carcinoma, which, so far, has been a disease with limited treatment options. However, in the current German S3 guideline for bladder cancer the remarkable improvements provided by immune checkpoint inhibitors have not been reflected. As cancer immunotherapy is a novel approach, there are several questions related to the daily clinical routine: What clinical data was used as the basis for the approval of the individual substances? What does this mean for previous treatment algorithms? What issues must be considered in the management of adverse events? What side-effects may occur and how can they be recognised and treated? The present paper provides an overview of the new treatment options regarding their relevance as well as recommendations for their application in clinical practice. Read More

    [Intra- and postoperative complications classified according to the Clavien-Dindo classification in patients > 80 years after transurethral resection of the urinary bladder].
    Aktuelle Urol 2018 Mar 8. Epub 2018 Mar 8.
    Malteser Krankenhaus St. Josefshospital Krefeld-Uerdingen.
    Introduction:  Urothelial carcinoma of the urinary bladder is a tumour of advanced age. The demographic change increases the number of very old patients ( > 80 years) subjected to TUR-B.

    Material And Methods:  In a retrospective analysis, perioperative complications in 89 patients (> 80 years), who underwent a transurethral resection of the bladder between 2013 and 2016 in our department, were recorded and evaluated using the Clavien-Dindo grading system. Read More

    [Vesicouterine fistula after caesarean section].
    Aktuelle Urol 2018 Feb 1;49(1):92-95. Epub 2018 Feb 1.
    Klinik für Urologie, Uro-Onkologie, spezielle urologische und roboter-assistierte Chirurgie, Universitätsklinikum Köln.
    Vesicouterine fistulas (VUFs) are a pathological communication between uterus and urinary bladder, which are mainly related to iatrogenic lesions during caesarean sections or occur during vaginal deliveries after a previous caesarean section. The main symptoms are menstruation through the bladder (menouria), amenorrhea and urinary incontinence. Treatment can be conservative, hormonal or surgical; however, a spontaneous closure of the fistula is rare (5 %). Read More

    [Diagnostic and therapeutic concepts for vesicovaginal and ureterovaginal fistulas].
    Aktuelle Urol 2018 Feb 1;49(1):83-91. Epub 2018 Feb 1.
    Klinik für Urologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg.
    Background:  Vesico- and ureterovaginal fistulas are defined as abnormal connections between the urinary tract, on the one side, and the female genital system, on the other. Despite being highly prevalent as an acquired pathology of the urogenital system, there has as yet been no standardized protocol in place for diagnosing and treating these fistulas. This review analyses the current literature concerning vesico- and ureterovaginal fistulas in order to profile common diagnostic and therapeutic concepts. Read More

    [Surgical management of female stress urinary incontinence].
    Aktuelle Urol 2018 Feb 1;49(1):78-82. Epub 2018 Feb 1.
    Klinik für Urologie, Uro-Onkologie, spezielle urologische und roboter-assistierte Chirurgie, Universitätsklinikum Köln.
    Stress urinary incontinence in women is a common problem in Germany, with approx. 5 million women suffering from incontinence symptoms. These numbers are increasing, due to demographic changes; the suspected numbers are even higher. Read More

    [Combined treatment of endometriosis: radical yet gentle].
    Aktuelle Urol 2018 Feb 1;49(1):60-72. Epub 2018 Feb 1.
    Klinik für Gynäkologie und Geburtshilfe, Kiel School of Gynecological Endoscopoy, Universitätsklinikum Schleswig-Holstein.
    Endometriosis is the second most common benign female genital disease after uterine myoma. This review discusses the management of individual patients. This should take into account the severity of the disease and whether the patient desires to have children. Read More

    [Surgical treatment of pelvic organ prolapse].
    Aktuelle Urol 2018 Feb 1;49(1):52-59. Epub 2018 Feb 1.
    Klinik für Urologie, Uro-Onkologie, spezielle urologische und roboter-assistierte Chirurgie, Universitätsklinikum Köln.
    Female pelvic organ prolapse is a widely prevalent condition and is associated with variable morbidity. It encompasses a number of clinical conditions, including subvesical obstruction, overactive bladder symptoms, sexual dysfunction and urinary und fecal incontinence. The prevalence of pelvic insufficiency is estimated to be between 30 and 50 %. Read More

    [Female stress incontinence: aspects of pathogenesis and functional anatomy].
    Aktuelle Urol 2018 Feb 1;49(1):47-51. Epub 2018 Feb 1.
    Urologische Klinik, Diakoniekrankenhaus, Schwäbisch Hall.
    This article focuses on female stress incontinence in the form of pelvic floor dysfunction and urethral sphincter deficiency, although isolated stress incontinence accounts for less than half of all incontinence cases. Especially in women of old age and those with neurological comorbidities, the causes of incontinence are mostly multifactorial. Also it has to be considered that the female bladder, urethra, uterus and rectum as well as the muscular and ligamentous structures of the female pelvis minor are affected by phases of fertility, possible pregnancies, births and menopause in addition to the normal ageing process. Read More

    Aktuelle Urol 2018 Feb 1;49(1):25-36. Epub 2018 Feb 1.
    Department of Urology und Pediatric Urology, Philipps University Marburg.
    In 2017, many new and promising therapeutic innovations entered uro-oncology. Immunotherapy was highly topical and was intensively discussed at the annual meetings. This review summarises the news, together with future developments in the diagnosis and treatment of prostate, bladder and kidney cancer. Read More

    [The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer].
    Aktuelle Urol 2018 Jan 25. Epub 2018 Jan 25.
    Klinik für Urologie, Universitätsklinikum Schleswig-Holstein - Campus Lübeck, 23538 Lübeck.
    A recently discovered mechanism enabling prostate cancer cells to escape the effects of endocrine therapies consists in the synthesis of C-terminally truncated, constitutively active androgen receptor (AR) splice variants (AR-V). Devoid of a functional C-terminal hormone/ligand binding domain, various AR-Vs are insensitive to therapies targeting the androgen/AR signalling axis. Preliminary studies suggest that AR-V7, the most common AR-V, is a promising predictive tumour marker and a relevant selection marker for the treatment of advanced prostate cancer. Read More

    [Conservative treatment options for female incontinence].
    Aktuelle Urol 2018 Feb 21;49(1):73-77. Epub 2017 Dec 21.
    Urologische Klinik und Poliklinik, Klinikum der Universität München, Ludwig-Maximilians-Universität München.
    In this narrative review, we give an overview of contemporary conservative treatment concepts for urinary incontinence in female patients. Hereby, we focus on pure stress urinary incontinence, urge incontinence and mixed urinary incontinence. We emphasise the value of rationally used diagnostic methods to be able to distinguish between these subentities. Read More

    1 OF 25